Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

900.92 +10.26 (+1.15%)
Streaming Delayed Price Updated: 2:33 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
Via Benzinga
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent. 
Via Benzinga
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today
Via Benzinga
Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views
Via Benzinga
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Small-Cap Growth Stocks With Room To Run
These two small-cap growth stocks could be ready to run. 
Via The Motley Fool
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
Via Benzinga
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
Via Benzinga
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
Via Benzinga
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
From Kirby McInerney LLP
Via GlobeNewswire
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300... 
Via Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
The U.S. Justice Department accuses Regeneron Pharmaceuticals of Medicare fraud related to its macular degeneration drug, Eylea. Allegations include manipulating drug prices, resulting in inflated... 
Via Benzinga
Topics Fraud
Exposures Legal
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?
Regeneron has fallen more than 6% over the past six weeks, and dropped again Thursday, as the DOJ focuses on its Eylea franchise. 
Via Investor's Business Daily
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Should You Sell This Stock Following a Regulatory Roadblock?
It's not the first such obstacle this high-performing drugmaker has faced. 
Via The Motley Fool
5 Healthcare Stocks to Buy for 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense. 
Via The Motley Fool
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.